1. In Search of Magic Bullets: The Golden Age of Immunotherapeutics
John J. O’Shea, Yuka Kanno, Andrew C. Chan 
Cell 
Volume 157, Issue 1, Pages (March 2014)
DOI: /j.cell
Copyright © 2014 Elsevier Inc. Terms and Conditions

2. Figure 1 Timeline of Targeted Therapies
Selected examples of recombinant cytokines and cytokine receptors, monoclonal antibodies (mAbs), and small molecules illustrate the evolution of targeted therapies.
Cell  , DOI: ( /j.cell )
Copyright © 2014 Elsevier Inc. Terms and Conditions

3. Figure 2 Lessons Learned and Challenges Ahead
Cell  , DOI: ( /j.cell )
Copyright © 2014 Elsevier Inc. Terms and Conditions

4. Figure 3 Flow of Information in Development of Targeted Therapies
Advances in molecular biology revealed a number of targets that were identified at the bench and led to successful drugs at the bedside (“bench to bedside”). Conversely, though, advances in sequencing technology led to the discovery of various genetic disorders that also provided convincing targets for intervention. Such “experiments of nature” facilitated the understanding of what the consequence of interfering with a target might be and thus provided impetus to go back to the bench (“bedside to bench to bedside”). In other circumstances, development of a targeted therapy did not have the expected result. Fortunately, in a number of cases, this led investigators to go back to the bedside and rethink disease mechanisms and find the right disease for the therapy (“bench to bedside to bedside”).
Cell  , DOI: ( /j.cell )
Copyright © 2014 Elsevier Inc. Terms and Conditions